IL17RB and breast carcinoma: Wen-Hwa and co-workers first reported that amplified IL-17B/IL-17RB signaling promotes breast cancer tumorigenicity by activating nuclear factor-kB, to upregulate the antiapoptotic factor Bcl-214.